

VEDLEGG I

**LISTE OVER NAVN, LEGEMIDDELFORM(ER), LEGEMIDDELSTYRKE(R),
ADMINISTRASJONSMÅTE(R), SØKER(E), INNEHAVER(E) AV
MARKEDSFØRINGSTILLATELSEN I MEDLEMSLANDENE**

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 20 mg Spritzampullen	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 40 mg Spritzampullen	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 60 mg Spritzampullen	60 mg	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 80 mg Spritzampullen	80 mg	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 100 mg Spritzampullen	100 mg	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 120 mg Spritzampullen	120 mg	Solution for injection	Subcutaneous use	0.8 ml (150 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 150 mg Spritzampullen	150 mg	Solution for injection	Subcutaneous use	1 ml (150 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 100 mg/ml Durchstichflasche	300 mg	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 100 mg/1 ml Ampullen	100 mg	Solution for injection	Subcutaneous use; Intravenous use	100 mg / 1,0 ml

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 100 mg/10 ml Stechampullen	100 mg	Solution for injection	Extracorporeal use	100 mg / 10 ml
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 10 x 40 mg Pen	40 mg	Solution for injection	Subcutaneous use	400,00 mg/3 ml (equiv. 10 single doses of 40 mg)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	20 mg/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use	0.2 ml (100 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	40 mg/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use	0.4 ml (100 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	60 mg/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	80 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	100 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	120 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (150 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	150 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (150 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	300 mg/3 ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Bulgaria	SANOFI BULGARIA EOOD 90 Tsarigradsko chaussee Blvd. Office building Capital Fort, section A, 10th floor Sofia 1784, Bulgaria	Clexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml (100 mg/ml)
Bulgaria	SANOFI BULGARIA EOOD 90 Tsarigradsko chaussee Blvd. Office building Capital Fort, section A, 10th floor Sofia 1784, Bulgaria	Clexane	60 mg /0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml)
Bulgaria	SANOFI BULGARIA EOOD 90 Tsarigradsko chaussee Blvd. Office building Capital Fort, section A, 10th floor Sofia 1784, Bulgaria	Clexane	80 mg /0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml)
Bulgaria	SANOFI BULGARIA EOOD 90 Tsarigradsko chaussee Blvd. Office building Capital Fort, section A, 10th floor Sofia 1784, Bulgaria	Clexane	300 mg /3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Croatia	sanofi-aventis Croatia d.o.o. Heinzlova 70, 10000 Zagreb, Croatia	Clexane 2000 IU anti-Xa/0,2 ml otopina za injekciju u napunjenoj štrcaljki	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Croatia	sanofi-aventis Croatia d.o.o. Heinzlova 70, 10000 Zagreb, Croatia	Clexane 4000 IU anti-Xa/0,4 ml otopina za injekciju u napunjenoj štrcaljki	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Croatia	sanofi-aventis Croatia d.o.o. Heinzlova 70, 10000 Zagreb, Croatia	Clexane 6000 IU anti-Xa/0,6 ml otopina za injekciju u napunjenoj štrcaljki	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Croatia	sanofi-aventis Croatia d.o.o. Heinzlova 70, 10000 Zagreb, Croatia	Clexane 8000 IU anti-Xa/0,8 ml otopina za injekciju u napunjenoj štrcaljki	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Croatia	sanofi-aventis Croatia d.o.o. Heinzlova 70, 10000 Zagreb, Croatia	Clexane 10 000 IU anti-Xa/1,0 ml otopina za injekciju u napunjenoj štrcaljki	10 000 anti- Xa IU/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Croatia	sanofi-aventis Croatia d.o.o. Heinzlova 70, 10000 Zagreb, Croatia	Clexane 30 000 IU anti-Xa/3,0 ml otopina za injekciju u višedoznom spremniku	30 000 anti- Xa IU/3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use	0.2 ml (100 mg/ml equivalent to 10000 anti-Xa IU/ml)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use	0.4 ml; (100 mg/ml equivalent to 10000 anti-Xa IU/ml)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml equivalent to 10000 anti-Xa IU/ml)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml equivalent to 10000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	150 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (150 mg/ml)
Czech Republic	sanofi-aventis, s.r.o. Evropská 846/176a 160 00 Praha 6 Czech Republic	Clexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Czech Republic	sanofi-aventis, s.r.o. Evropská 846/176a 160 00 Praha 6 Czech Republic	Clexane Forte	150 mg/ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml; 1.0 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Denmark	sanofi-aventis Denmark A/S Slotsmarken 13 2970 Hørsholm Denmark	Klexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Denmark	sanofi-aventis Denmark A/S Slotsmarken 13 2970 Hørsholm Denmark	Klexane	100 mg/ml	Solution for injection	Subcutaneous use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Estonia	sanofi-aventis Estonia OÜ Pärnu mnt. 139 E/2 11317 Tallinn, Estonia	Clexane	10 000 anti- Xa IU/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml equivalent to 10000 anti-Xa IU/ml)
Finland	Sanofi Oy Huopalahdentie 24 00350 Helsinki Finland	Klexane	100 mg/ml	Solution for injection	Subcutaneous use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)
Finland	Sanofi Oy Huopalahdentie 24 00350 Helsinki Finland	Klexane Cum Conservans	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml; 10 ml (100 mg/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 2000 UI anti-Xa/0,2 ml, solution injectable en seringue préremplie	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 4000 UI anti-Xa/0,4 ml, solution injectable en seringue préremplie	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 6000 UI anti-Xa/0,6 ml, solution injectable en seringue préremplie	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 8000 UI anti-Xa/0,8 ml, solution injectable en seringue préremplie	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 10 000 UI anti-Xa/1 ml, solution injectable en seringue préremplie	10 000 anti- Xa IU/1 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 30 000 UI Anti-Xa/3 ml, solution injectable en flacon multidose	30 000 anti- Xa IU/3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 2000 UI anti-Xa/0,2 ml, solution injectable en seringue préremplie	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 4000 UI anti-Xa/0,4 ml, solution injectable en seringue préremplie	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 6000 UI anti-Xa/0,6 ml, solution injectable en seringue préremplie	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 8000 UI anti-Xa/0,8 ml, solution injectable en seringue préremplie	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 10 000 UI anti-Xa/1 ml, solution injectable en seringue préremplie	10 000 anti- Xa IU/1 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 20mg	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 20 mg Klinik	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 20 mg Praxis	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 20 mg	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 40 mg	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 40 mg Praxis	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 40 mg Klinik	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 40 mg	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 60 mg	60 mg	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 60 mg Fertigspritzen	60 mg	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 80 mg	80 mg	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 80 mg Fertigspritzten	80 mg	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 100 mg	100 mg	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 100 mg Fertigspritzten	100 mg	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi multidose 100 mg/ml	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane multidose 100 mg/ml	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane Multidose 100 mg/ml Praxis	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Qualiop multidose 100 mg/ml	100 mg/ml	Solution for injection	Subcutaneous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Qualiop Klinik 100 mg/ml	100 mg/ml	Solution for injection	Subcutaneous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	2000 anti-Xa IU /0.2 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	4000 anti-Xa IU /0.4 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	6000 anti-Xa IU /0.6 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	8000 anti-Xa IU /0.8 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	12000 anti- Xa IU /0.8 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.8 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	15000 anti- Xa IU /1.0 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	1 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	20 mg (2000 NE /0.2 ml)	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	40 mg (4000 NE /0.4 ml)	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	60 mg (6000 NE /0.6 ml)	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	80 mg (8000 NE /0.8 ml)	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	100 mg (10 000 NE/1 ml)	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	300 mg (30 000 NE/3 ml)	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane Forte	120 mg/0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (150 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane Forte	150 mg/1.0 ml	Solution for injection	Subcutaneous use	1.0 ml (150 mg/ml)
Iceland	Sanofi-aventis Norge AS P.O.Box 133 1325 Lysaker Norway	Klexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Iceland	Sanofi-aventis Norge AS P.O.Box 133 1325 Lysaker Norway	Klexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml)
Ireland	Sanofi-aventis Ireland Ltd T/A SANOFI Citywest Business Campus Dublin 24 Ireland	Clexane Syringes	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1 ml (100 mg/ml)
Ireland	Sanofi-aventis Ireland Ltd T/A SANOFI Citywest Business Campus Dublin 24 Ireland	Clexane Forte Syringe	150 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml; 1 ml (150 mg/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane T	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane T	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane T	10 000 anti- Xa IU/1.0 ml	Solution for injection	Subcutaneous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane T	30 000 anti- Xa IU/3.0 ml	Solution for injection	Intravenous use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Latvia	sanofi – aventis Latvia SIA 33 - 8 Kr. Valdemāra Street Rīga, LV - 1010 Latvia	Clexane 2000 anti- Xa SV/0,2 ml šķīdums injekcijām pilnšjircē	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Latvia	sanofi – aventis Latvia SIA 33 - 8 Kr. Valdemāra Street Rīga, LV - 1010 Latvia	Clexane 4000 anti- Xa SV/0,4 ml šķīdums injekcijām pilnšjircē	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Latvia	sanofi – aventis Latvia SIA 33 - 8 Kr. Valdemāra Street Rīga, LV - 1010 Latvia	Clexane 6000 anti- Xa SV/0,6 ml šķīdums injekcijām pilnšjircē	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Latvia	sanofi – aventis Latvia SIA 33 - 8 Kr. Valdemāra Street Rīga, LV - 1010 Latvia	Clexane 8000 anti- Xa SV/0,8 ml šķīdums injekcijai pilnšjircē	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Lithuania	UAB "SANOFI-AVENTIS LIETUVA" A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 2 000 anti- Xa TV/0,2 ml injekcinis tirpalas užpildytame švirkšte	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Lithuania	UAB "SANOFI-AVENTIS LIETUVA" A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 4 000 anti- Xa TV/0,4 ml injekcinis tirpalas užpildytame švirkšte	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Lithuania	UAB "SANOFI-AVENTIS LIETUVA" A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 6 000 anti- Xa TV/0,6 ml injekcinis tirpalas užpildytame švirkšte	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Lithuania	UAB "SANOFI-AVENTIS LIETUVA" A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 8 000 anti- Xa TV/0,8 ml injekcinis tirpalas užpildytame švirkšte	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Lithuania	UAB "SANOFI-AVENTIS LIETUVA" A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 10 000 anti-Xa TV/1,0 ml injekcinis tirpalas užpildytame švirkšte	10 000 anti- Xa IU/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	20 mg/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use	0.2 ml (100 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	40 mg/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use	0.4 ml (100 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	60 mg/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	80 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	100 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	120 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (150 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	150 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (150 mg/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	2000 anti-Xa IU /0.2 ml (20 mg/0.2 ml)	Solution for Injection	Subcutaneous use; Intravenous use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	4000 anti-Xa IU /0.4 ml (40 mg/0.4 ml)	Solution for Injection	Subcutaneous use; Intravenous use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	6000 anti-Xa IU /0.6 ml (60 mg/0.6 ml)	Solution for Injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	8000 anti-Xa IU /0.8 ml (80 mg/0.8 ml)	Solution for Injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	10 000 anti- Xa IU /1.0 ml (100 mg/1 ml)	Solution for Injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane Forte Syringes	120 mg/0.8 ml	Solution for Injection	Subcutaneous use; Intravenous use	0.8 ml (150 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane Forte Syringes	150 mg/1.0 ml	Solution for Injection	Subcutaneous use; Intravenous use	1 ml (150 mg/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane Multidose vial	30 000 anti- Xa IU /3.0 ml (300 mg/3 ml)	Solution for Injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Netherlands	sanofi-aventis Netherlands B.V. Kampenringweg 45 D-E 2803 PE Gouda The Netherlands	Clexane 100 mg/ml	100 mg/ml	Solution for Injection	Subcutaneous use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)
Netherlands	sanofi-aventis Netherlands B.V. Kampenringweg 45 D-E 2803 PE Gouda The Netherlands	Clexane 300 mg/3 ml	300 mg/ 3ml	Solution for Injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Netherlands	sanofi-aventis Netherlands B.V. Kampenringweg 45 D-E 2803 PE Gouda The Netherlands	Clexane 150 mg/ml	150 mg/ml	Solution for Injection	Subcutaneous use	0.8 ml; 1.0 ml (150 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Norway	Sanofi-aventis Norge AS Postboks 133 1325 Lysaker Norway	Klexane	100 mg/ml	Injeksjonsvæske, oppløsning	Subkutan bruk; Intravenøs bruk; Ekstrakorporal bruk	0,2 ml; 0,4 ml; 0,6 ml; 0,8 ml; 1,0 ml (100 mg/ml)
Norway	Sanofi-aventis Norge AS Postboks 133 1325 Lysaker Norway	Klexane	100 mg/ml	Injeksjonsvæske, oppløsning	Subkutan bruk; Intravenøs bruk; Ekstrakorporal bruk	3 ml (100 mg/ml)
Norway	Sanofi-aventis Norge AS Postboks 133 1325 Lysaker Norway	Klexane	150 mg/ml	Injeksjonsvæske, oppløsning	Subkutan bruk; Intravenøs bruk; Ekstrakorporal bruk	0,8 ml; 1,0 ml (150 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	20 mg /0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	40 mg /0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	60 mg /0.6 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.6 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	80 mg /0.8 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml (100 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	100 mg /1 ml	Solution for injection	Subcutaneous use; Extracorporeal use	1 ml (100 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	300 mg /3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml)
Poland	Aventis Pharma Limited One Onslow Street Guildford, Surrey GU1 4YS United Kingdom	Clexane forte	120 mg /0.8 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml (150 mg/ml)
Poland	Aventis Pharma Limited One Onslow Street Guildford, Surrey GU1 4YS United Kingdom	Clexane forte	150 mg /1 ml	Solution for injection	Subcutaneous use; Extracorporeal use	1 ml (150 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	100 mg/1 ml	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	150 mg/1 ml	Solution for injection	Subcutaneous use	1 ml (150 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	80 mg/ 0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	60 mg/ 0.6 ml	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	40 mg/ 0.4 ml	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	20 mg/ 0.2 ml	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	120 mg/ 0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (120 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Romania	Sanofi Romania SRL, Strada Gara Herăstrău, nr. 4, Clădirea B, etajele 8-9, Sector 2, București, Romania	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Romania	Sanofi Romania SRL, Strada Gara Herăstrău, nr. 4, Clădirea B, etajele 8-9, Sector 2, București, Romania	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Romania	Sanofi Romania SRL, Strada Gara Herăstrău, nr. 4, Clădirea B, etajele 8-9, Sector 2, București, Romania	Clexane	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Romania	Sanofi Romania SRL, Strada Gara Herăstrău, nr. 4, Clădirea B, etajele 8-9, Sector 2, București, Romania	Clexane	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	10 000 anti- Xa IU/1 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	30 000 anti- Xa IU/3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane forte	12000 anti- Xa IU /0.8 ml	solution for injection	Subcutaneous use	0.8 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane forte	15000 anti- Xa IU /1.0 ml	solution for injection	Subcutaneous use	1 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	10 000 anti- Xa IU/1 ml	Solution for injection	Subcutaneous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	10 000 anti- Xa IU/ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	12000 anti- Xa IU /0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	15000 anti- Xa IU /1 ml	Solution for injection	Subcutaneous use	1 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 20 mg (2.000 UI) solución inyectable en jeringa precargada	20 mg (2000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 40 mg (4.000 UI) solución inyectable en jeringa precargada	40 mg (4000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 60 mg (6.000 UI) solución inyectable en jeringa precargada	60 mg (6000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 80 mg (8.000 UI) solución inyectable en jeringa precargada	80 mg (8000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 100 mg (10.000 UI) solución inyectable en jeringa precargada	100 mg (10 000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 120 mg (12.000 UI) solución inyectable en jeringa precargada	120 mg (12000 IU)	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml (150 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 150 mg (15.000 UI) solución inyectable en jeringa precargada	150 mg (15000 IU)	Solution for injection	Subcutaneous use; Extracorporeal use	1 ml (150 mg/ml)
Sweden	Sanofi AB Box 30052 104 25 Stockholm Sweden	Klexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
Sweden	Sanofi AB Box 30052 104 25 Stockholm Sweden	Klexane (med konserveringsmedel)	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml; 10 ml (100 mg/ml)
Sweden	Sanofi AB Box 30052 104 25 Stockholm Sweden	Klexane	150 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml; 0.8 ml; 1.0 ml (150 mg/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	20 mg/ 0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	40 mg /0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	60 mg/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 IU anti-Xa activity/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	80 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	100 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml equivalent to 10000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Forte Syringes	120 mg/0.8 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml (150 mg/ml equivalent to 15000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Forte Syringes	150 mg/1.0 ml	Solution for injection	Subcutaneous use; Extracorporeal use	1 ml (150 mg/ml equivalent to 15000 IU anti-Xa activity/ml)

Medlemsland EU/EØS	Innehaver av markedsføringstillatelse	Navn	Styrke	Legemiddelform	Administrasjonsvei	Innhold (Konsentrasjon)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Multidose vial	300 mg/3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml)